相关实验视频

Updated: Sep 19, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

发现和药理学评估强效和高度选择性的PARP1抑制剂

Tao Guo¹, Yongting Yuan¹, Ziyan Ma²

¹Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

Journal of medicinal chemistry

|June 18, 2025

概括

研究人员开发了一种选择性PARP1抑制剂, (S) - G9,以减少毒性. 这种新型化合物对PARP1具有很高的疗效,抑制瘤生长,并且在与化疗相结合时可能改善癌症治疗.

科学领域:

在瘤学瘤学.
药用化学医学化学
分子生物学分子生物学

背景情况:

第一代多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 针对PARP1和PARP2,导致潜在的血液毒性.
开发PARP1选择性抑制剂对于提高癌症治疗疗效和安全至关重要.

研究的目的:

设计和合成具有对PARP1比PARP2高选择性的新型小分子.
为了评估化合物 (S) - G9作为PARP1选择性抑制剂的体外和体内疗效.

主要方法:

针对PARP1.1的小分子的合成.
在体外酶分析以确定IC50值和对PARP1和PARP2的选择性.
在BRCA突变癌细胞中进行基于细胞的抗增殖试验.
在小鼠模型中进行体内异种移植研究,以评估瘤生长抑制和组合疗效.

主要成果:

(S) - G9显示出强烈的PARP1抑制,IC50为0.19nM,对PARP2的选择性是137倍.
(S) - G9对BRCA突变MDA-MB-436细胞表现出高的抗增殖活性 (IC50=1.5nM),并充当PARP1选择性诱捕者.
在BRCA突变异体移植模型中, (S) - G9抑制了瘤生长,在另一种异体移植模型中,它与伊利诺特干产生了协同效应.

结论:

开发的策略成功产生了一种高度选择性的PARP1抑制剂, (S) -G9.
(S) - G9显示为癌症治疗剂的前景,特别是与化疗结合使用.
选择性PARP1抑制在向癌症疗法开发方面取得了重大进展.

更多相关视频

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are: